Cytokinetics and Astellas Pharma Join Forces to Fight Muscle Disease

Cytokinetics, Inc., the San Francisco-based company currently conducting a Phase II ALS clinical trial of the fast skeletal troponin muscle activator tirasemtiv, has signed a $490 million collaboration with Astellas Pharma, Inc. The two companies will be working together to develop new skeletal muscle activators, with Astellas Pharma focusing on non-neuromuscular indications and Cytokinetics focusing on neuromuscular targets including ALS. Unfortunately, the Phase II tirasemtiv trial had a recent setback due to a computer programming error that resulted in 58 patients receiving placebo instead of the study drug, but Cytokinetics has corrected the error and the trial is back on track.

Cytokinetics, Inc., the San Francisco-based company currently conducting a Phase II ALS clinical trial of the fast skeletal troponin muscle activator tirasemtiv, has signed a $490 million collaboration with Astellas Pharma, Inc. The two companies will be working together to develop new skeletal muscle activators, with Astellas Pharma focusing on non-neuromuscular indications and Cytokinetics focusing on neuromuscular targets including ALS. Unfortunately, the Phase II tirasemtiv trial had a recent setback due to a computer programming error that resulted in 58 patients receiving placebo instead of the study drug, but Cytokinetics has corrected the error and the trial is back on track.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail